Gilead Sciences’ antiviral drug candidate remdesivir has led to quick recoveries in symptoms of Covid-19 patients in a clinical trial, according to a report by STAT news agency.
STAT is said to have obtained a copy of a video discussion by a University of Chicago faculty member overseeing the study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the partial data reported, participants treated with remdesivir experienced rapid recoveries in fever and respiratory symptoms and nearly all patients were discharged within one week.
